Abstract
The current gold-standard for estimating value in health-technology assessments is the incremental-cost-effectiveness ratio. However, alternative methods of assessing value may be required in the future as societal priorities change. One example is a value-metric for new therapies based on their carbon footprint. This would be aligned with wider long-term public policy objectives and support carbon emission reduction targets. Here we provide a conceptual model to estimate the carbon footprint of chronic kidney disease (CKD).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
